

**What is the future direction of the management of elderly patients with acute myeloid leukemia?**

**Aziz Nazha, MD**

Assistant Professor, Lerner College of Medicine  
Associate Staff, Taussig Cancer Institute  
Cleveland Clinic  
Cleveland, Ohio

Welcome to *Managing AML*, I am Dr. Aziz Nazha. I am frequently asked, “What is the future direction of the management of elderly patients with acute myeloid leukemia?” Given the poor outcome of elderly patients with acute myeloid leukemia, the treatment recommendation should always be a clinical trial. Clinical trials are the only options for us to improve the outcomes for those patients. I think the direction that we might need to move forward in is to identify the patients that can receive intensive chemotherapy. Hopefully we can improve on 7+3, identify the patients that can have molecularly targeted therapy, isolate those patients, and see if we can improve the outcome of the combination of these inhibitors; such as FLT3 inhibitors, IDH inhibitors, with chemotherapy or other treatment approaches. Then, identify the patients who may not qualify to receive intensive chemotherapy and provide them with a less intensive approach, whether this is a hypomethylating agent plus another novel agent, or the introduction of more novel agents that typically have less side effects and can be more effective in the treatment of patients with AML. Thank you very much for viewing this activity.